All Products

Featured Products

Newest Products

Research Areas

Firategrast
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319612

CAS#: 402567-16-2

Description: Firategrast, also known as SB-683699 or T-0047, is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. The integrins are a sort of transmembrane receptors that modulate the signal transduction from ECM to the cell. They are associated with a lot of diseases such as cancer, inflammation and thrombotic diseases.


Price and Availability

Size Price Shipping out time Quantity
50mg USD 650 2 Weeks
100mg USD 950 2 Weeks
200mg USD 1650 2 Weeks
500mg USD 2650 2 Weeks
1g USD 3450 2 Weeks
2g USD 4950 2 Weeks
Inquire bulk and customized quantity
Pricing updated 2020-10-23. Prices are subject to change without notice.

Firategrast, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319612
Name: Firategrast
CAS#: 402567-16-2
Chemical Formula: C27H27F2NO6
Exact Mass: 499.1806
Molecular Weight: 499.5108
Elemental Analysis: C, 64.92; H, 5.45; F, 7.61; N, 2.80; O, 19.22


Synonym: SB-683699; SB 683699; SB683699; T-0047; T 0047; T0047; Firategrast

IUPAC/Chemical Name: (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid

InChi Key: YLFZHHDVRSYTKT-NRFANRHFSA-N

InChi Code: InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1

SMILES Code: O=C(O)[C@@H](NC(C1=C(F)C=CC=C1F)=O)CC2=CC=C(C3=C(OC)C=C(COCC)C=C3OC)C=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Halland N, Blum H, Buning C, Kohlmann M, Lindenschmidt A. Small Macrocycles As
Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett. 2014 Jan
10;5(2):193-8. doi: 10.1021/ml4004556. eCollection 2014 Feb 13. PubMed PMID:
24900800; PubMed Central PMCID: PMC4027761.

2: Lu E, Wang BW, Alwan S, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A
review of safety-related pregnancy data surrounding the oral disease-modifying
drugs for multiple sclerosis. CNS Drugs. 2014 Feb;28(2):89-94. doi:
10.1007/s40263-013-0131-5. Review. PubMed PMID: 24343726.

3: Grove RA, Shackelford S, Sopper S, Pirruccello S, Horrigan J, Havrdova E, Gold
M, Graff O. Leukocyte counts in cerebrospinal fluid and blood following
firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur
J Neurol. 2013 Jul;20(7):1032-42. doi: 10.1111/ene.12097. Epub 2013 Feb 18.
PubMed PMID: 23419064.

4: Prat A, Stüve O. Firategrast: natalizumab in a pill? Lancet Neurol. 2012
Feb;11(2):120-1. doi: 10.1016/S1474-4422(11)70306-4. Epub 2012 Jan 5. PubMed
PMID: 22226930.

5: Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua
P, Yousry T, Macmanus D, Montalban X. Firategrast for relapsing remitting
multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled
trial. Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X.
Epub 2012 Jan 5. PubMed PMID: 22226929.